Gilead Sciences, Inc. vs Matson Inc — how do they compare? Gilead Sciences, Inc. trades at $136.32 (market cap $168.35B), while Matson Inc trades at $214.74 (market cap $6.11B). The key difference: Gilead Sciences, Inc. is far larger — about 27.6× Matson Inc's market cap, and Gilead Sciences, Inc. pays the higher dividend (2.42%). Which is the better fit depends on your goals.
| GILD | MATX | |
|---|---|---|
Market Cap | $168.35B | $6.11B |
Sector | Health | Technology |
52-Week High | $155.80 | $223.55 |
52-Week Low | $110.56 | $88.05 |
Enterprise Value | $191.42B | $6.71B |
Dividend Yield | 2.42% | 0.74% |
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $135.78, up 2.04% on the day, with a bullish technical signal and strong support at $134. Recent Q2 2026 earnings beat revenue estimates despite a net loss, driven by 10% base business growth from HIV drugs like Biktarvy. The company raised its full-year sales outlook, but faces a negative net income margin of -10.64% and elevated debt levels.
The outlook is mixed: robust HIV franchise growth and a 67% analyst buy rating support upside to the $151.22 consensus target, but acquisition costs, patent cliff risks, and volatile cash flows pose challenges. Investment appeal hinges on pipeline execution offsetting margin pressure.
Matson (MATX) trades at $214.52, up 2.8% today, with strong technical momentum and bullish moving averages. The company demonstrates solid fundamentals with consistent earnings beats, a 13.41% net margin, and robust cash flow generation. Recent Q2 2026 results exceeded expectations with EPS of $4.27 versus $3.79 estimate, driving positive analyst sentiment.
Outlook remains positive with 27% upside to consensus target of $265. Key risks include shipping industry cyclicality and global trade volatility. The combination of strong earnings momentum, attractive valuation at 13.79 P/E, and institutional support supports a constructive investment case for the stock.
Trailing returns across standard periods
Latest headlines on both assets
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →Matson, Inc. is an American shipping and logistics company primarily operating in the Pacific. The company provides ocean transportation services, including container, automobile, and general cargo, particularly between the U.S. West Coast, Hawaii, Alaska, and Guam. Matson also offers logistics services, including warehousing, less-than-container load (LCL) consolidation, and supply chain management, making it a critical service provider for businesses operating across the Pacific region.
Read more on MATX →